PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL

Dalia El-Gamal, Katie Williams, Taylor D. LaFollette, Matthew Cannon, James S. Blachly, Yiming Zhong, Jennifer A. Woyach, Erich Williams, Farrukh T. Awan, Jeffrey Jones, Leslie Andritsos, Kami Maddocks, Chia Hsien Wu, Ching Shih Chen, Amy Lehman, Xiaoli Zhang, Rosa Lapalombella, John C. Byrd

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Targeting B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) has been successful with durable remissions observed with several targeted therapeutics. Protein kinase C-β (PKC-β) is immediately downstream of BCR and has been shown to be essential to CLL cell survival and proliferation in vivo. We therefore evaluated sotrastaurin (AEB071), an orally administered potent PKC inhibitor, on CLL cell survival both in vitro and in vivo. AEB071 shows selective cytotoxicity against B-CLL cells in a dose-dependent manner. Additionally, AEB071 attenuates BCR-mediated survival pathways, inhibits CpG-induced survival and proliferation of CLL cells in vitro, and effectively blocks microenvironment-mediated survival signaling pathways in primary CLL cells. Furthermore, AEB071 alters β-catenin expression, resulting in decreased downstream transcriptional genes as c-Myc, Cyclin D1, and CD44. Lastly, our preliminary in vivo studies indicate beneficial antitumor properties of AEB071 in CLL. Taken together, our results indicate that targeting PKC-β has the potential to disrupt signaling from the microenvironment contributing to CLL cell survival and potentially drug resistance. Future efforts targeting PKC with the PKC inhibitor AEB071 asmonotherapy in clinical trials of relapsed and refractory CLL patients are warranted.

Original languageEnglish (US)
Pages (from-to)1481-1491
Number of pages11
JournalBlood
Volume124
Issue number9
DOIs
StatePublished - Aug 28 2014

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Protein Kinase C
Cells
Cell Survival
B-Lymphocytes
Therapeutics
Survival
Catenins
Cyclin D1
Cytotoxicity
sotrastaurin
myc Genes
Refractory materials
Genes
Drug Resistance
Cell Proliferation
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

El-Gamal, D., Williams, K., LaFollette, T. D., Cannon, M., Blachly, J. S., Zhong, Y., ... Byrd, J. C. (2014). PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. Blood, 124(9), 1481-1491. https://doi.org/10.1182/blood-2014-05-574830

PKC-β as a therapeutic target in CLL : PKC inhibitor AEB071 demonstrates preclinical activity in CLL. / El-Gamal, Dalia; Williams, Katie; LaFollette, Taylor D.; Cannon, Matthew; Blachly, James S.; Zhong, Yiming; Woyach, Jennifer A.; Williams, Erich; Awan, Farrukh T.; Jones, Jeffrey; Andritsos, Leslie; Maddocks, Kami; Wu, Chia Hsien; Chen, Ching Shih; Lehman, Amy; Zhang, Xiaoli; Lapalombella, Rosa; Byrd, John C.

In: Blood, Vol. 124, No. 9, 28.08.2014, p. 1481-1491.

Research output: Contribution to journalArticle

El-Gamal, D, Williams, K, LaFollette, TD, Cannon, M, Blachly, JS, Zhong, Y, Woyach, JA, Williams, E, Awan, FT, Jones, J, Andritsos, L, Maddocks, K, Wu, CH, Chen, CS, Lehman, A, Zhang, X, Lapalombella, R & Byrd, JC 2014, 'PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL', Blood, vol. 124, no. 9, pp. 1481-1491. https://doi.org/10.1182/blood-2014-05-574830
El-Gamal, Dalia ; Williams, Katie ; LaFollette, Taylor D. ; Cannon, Matthew ; Blachly, James S. ; Zhong, Yiming ; Woyach, Jennifer A. ; Williams, Erich ; Awan, Farrukh T. ; Jones, Jeffrey ; Andritsos, Leslie ; Maddocks, Kami ; Wu, Chia Hsien ; Chen, Ching Shih ; Lehman, Amy ; Zhang, Xiaoli ; Lapalombella, Rosa ; Byrd, John C. / PKC-β as a therapeutic target in CLL : PKC inhibitor AEB071 demonstrates preclinical activity in CLL. In: Blood. 2014 ; Vol. 124, No. 9. pp. 1481-1491.
@article{155669644af1460782650f499174d064,
title = "PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL",
abstract = "Targeting B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) has been successful with durable remissions observed with several targeted therapeutics. Protein kinase C-β (PKC-β) is immediately downstream of BCR and has been shown to be essential to CLL cell survival and proliferation in vivo. We therefore evaluated sotrastaurin (AEB071), an orally administered potent PKC inhibitor, on CLL cell survival both in vitro and in vivo. AEB071 shows selective cytotoxicity against B-CLL cells in a dose-dependent manner. Additionally, AEB071 attenuates BCR-mediated survival pathways, inhibits CpG-induced survival and proliferation of CLL cells in vitro, and effectively blocks microenvironment-mediated survival signaling pathways in primary CLL cells. Furthermore, AEB071 alters β-catenin expression, resulting in decreased downstream transcriptional genes as c-Myc, Cyclin D1, and CD44. Lastly, our preliminary in vivo studies indicate beneficial antitumor properties of AEB071 in CLL. Taken together, our results indicate that targeting PKC-β has the potential to disrupt signaling from the microenvironment contributing to CLL cell survival and potentially drug resistance. Future efforts targeting PKC with the PKC inhibitor AEB071 asmonotherapy in clinical trials of relapsed and refractory CLL patients are warranted.",
author = "Dalia El-Gamal and Katie Williams and LaFollette, {Taylor D.} and Matthew Cannon and Blachly, {James S.} and Yiming Zhong and Woyach, {Jennifer A.} and Erich Williams and Awan, {Farrukh T.} and Jeffrey Jones and Leslie Andritsos and Kami Maddocks and Wu, {Chia Hsien} and Chen, {Ching Shih} and Amy Lehman and Xiaoli Zhang and Rosa Lapalombella and Byrd, {John C.}",
year = "2014",
month = "8",
day = "28",
doi = "10.1182/blood-2014-05-574830",
language = "English (US)",
volume = "124",
pages = "1481--1491",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - PKC-β as a therapeutic target in CLL

T2 - PKC inhibitor AEB071 demonstrates preclinical activity in CLL

AU - El-Gamal, Dalia

AU - Williams, Katie

AU - LaFollette, Taylor D.

AU - Cannon, Matthew

AU - Blachly, James S.

AU - Zhong, Yiming

AU - Woyach, Jennifer A.

AU - Williams, Erich

AU - Awan, Farrukh T.

AU - Jones, Jeffrey

AU - Andritsos, Leslie

AU - Maddocks, Kami

AU - Wu, Chia Hsien

AU - Chen, Ching Shih

AU - Lehman, Amy

AU - Zhang, Xiaoli

AU - Lapalombella, Rosa

AU - Byrd, John C.

PY - 2014/8/28

Y1 - 2014/8/28

N2 - Targeting B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) has been successful with durable remissions observed with several targeted therapeutics. Protein kinase C-β (PKC-β) is immediately downstream of BCR and has been shown to be essential to CLL cell survival and proliferation in vivo. We therefore evaluated sotrastaurin (AEB071), an orally administered potent PKC inhibitor, on CLL cell survival both in vitro and in vivo. AEB071 shows selective cytotoxicity against B-CLL cells in a dose-dependent manner. Additionally, AEB071 attenuates BCR-mediated survival pathways, inhibits CpG-induced survival and proliferation of CLL cells in vitro, and effectively blocks microenvironment-mediated survival signaling pathways in primary CLL cells. Furthermore, AEB071 alters β-catenin expression, resulting in decreased downstream transcriptional genes as c-Myc, Cyclin D1, and CD44. Lastly, our preliminary in vivo studies indicate beneficial antitumor properties of AEB071 in CLL. Taken together, our results indicate that targeting PKC-β has the potential to disrupt signaling from the microenvironment contributing to CLL cell survival and potentially drug resistance. Future efforts targeting PKC with the PKC inhibitor AEB071 asmonotherapy in clinical trials of relapsed and refractory CLL patients are warranted.

AB - Targeting B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) has been successful with durable remissions observed with several targeted therapeutics. Protein kinase C-β (PKC-β) is immediately downstream of BCR and has been shown to be essential to CLL cell survival and proliferation in vivo. We therefore evaluated sotrastaurin (AEB071), an orally administered potent PKC inhibitor, on CLL cell survival both in vitro and in vivo. AEB071 shows selective cytotoxicity against B-CLL cells in a dose-dependent manner. Additionally, AEB071 attenuates BCR-mediated survival pathways, inhibits CpG-induced survival and proliferation of CLL cells in vitro, and effectively blocks microenvironment-mediated survival signaling pathways in primary CLL cells. Furthermore, AEB071 alters β-catenin expression, resulting in decreased downstream transcriptional genes as c-Myc, Cyclin D1, and CD44. Lastly, our preliminary in vivo studies indicate beneficial antitumor properties of AEB071 in CLL. Taken together, our results indicate that targeting PKC-β has the potential to disrupt signaling from the microenvironment contributing to CLL cell survival and potentially drug resistance. Future efforts targeting PKC with the PKC inhibitor AEB071 asmonotherapy in clinical trials of relapsed and refractory CLL patients are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84907322714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907322714&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-05-574830

DO - 10.1182/blood-2014-05-574830

M3 - Article

C2 - 25001469

AN - SCOPUS:84907322714

VL - 124

SP - 1481

EP - 1491

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -